efficacy of intravenous iron therapy vs oral iron therapy on haemoglobin, exercise tolerance, cardiovascular risk and quality of life in patients having heart failure in mild to moderate iron deficiency anaemia

This is an open-label randomized controlled trial that aims to evaluate the efficacy of intravenous (IV) iron therapy versus oral iron supplementation in heart failure (HF) patients with mild to moderate iron deficiency anemia.The study will be carried out patients who are admitted Medicine ward  of Acharya Vinoba Bhave Rural Hospital (AVBRH) of Jawaharlal Nehru Medical College, Sawangi, Wardha from 2023 to 2025.Heart failure (HF) is a prevalent condition, especially among adults over 65, leading to significant morbidity and mortality. A common comorbidity in these patients is iron deficiency anemia, with prevalence estimates ranging from 4% to 30%. This comorbidity exacerbates clinical outcomes, increasing hospitalizations, impairing exercise capacity, diminishing quality of life, and elevating mortality risk. Data will be collected through face-to-face interviews with heart failure patients experiencing iron deficiency anemia at AVBRH, following written consent. Two groups will be formed: one receiving intravenous iron therapy (Inj ferric carboxymaltose) and the other oral iron therapy.  Baseline assessment of Hemoglobin levels, serum ferritin, serum iron, New York Heart Association (NYHA) classification, Six-Minute Walk Test (6MWT), and quality of life evaluation using the WHOQOL-100 questionnaire and follow up will be done at 3 months and 9 months. Adverse effects will be monitored throughout the study.